Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Lymphoma × sapanisertib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Recurrent Malignant Solid Neoplasm 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Metastatic Castration-Resistant Prostate Cancer 1 Malignant Neoplasms of Digestive Organs 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma 1 Liver Neoplasms 1 Fallopian Tube Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Merkel Cell 1 Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 272 Rituximab 243 Etoposide 136 Filgrastim 128 fludarabine phosphate 105 Cytarabine 98 Vincristine 97 Radiotherapy 96 Melphalan 95 Doxorubicin 90 Peripheral Blood Stem Cell Transplantation 82 Methotrexate 80 fludarabine 78 Prednisone 78 Busulfan 77 Tacrolimus 54 Whole-Body Irradiation 52 Mycophenolic Acid 52 Granulocyte Colony-Stimulating Factor 52 Dexamethasone 52 Antilymphocyte Serum 51 Carmustine 49 Cyclosporine 39 Lenalidomide 38 Methylprednisolone 37 Bortezomib 37 Bendamustine Hydrochloride 34 sargramostim 33 Stem Cell Transplantation 31 Ifosfamide 31

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02727777 2020-03-12

Phase II Study of TAK228 in Relapsed Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated

4 enrolled 9 charts

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡